[1] Fowler NH, Mclaughlin P, Kwak L, et al.Lenalidomide and rituximab for untreated indolent non-Hodgkin’s lymphoma[J]. J Clin Oncol, 2009, 27(15): 8548. [2] Wiernik PH, Lossos IS, Tuscano JM, et al.Lenalidomide mono- therapy in relapsed or refractory aggressive non-Hodgkin's lymphoma[J]. J Clin Oncol, 2008, 26(30): 4952-4957. [3] 邵震,王俊淞.顺铂致430例药品不良反应报告分析[J].中国药物经济学, 2017, 12(11): 19-21. [4] 邱爽,崔向丽,王颖. 112例吉西他滨不良反应分析[J].中国新药杂志, 20l4, 23(17): 2085-2088. [5] 周莉莉,傅卫军,侯健.地塞米松治疗多发性骨髓瘤引起心动过缓二例病例分析[J]. 中华血液学杂志, 2010, 31(1): 48-49. [6] 梁佳. 利妥昔单抗致心律失常1例[J].医药导报, 2016, 35(8): 900. [7] 李晋文,章萍,廖应熙,等.利妥昔单抗注射液致过敏反应及阵发性室上性心动过速1例[J].中国药物警戒, 2019, 16(8):504-505, 507. [8] Katodritou E, Vadikolia C, Lalagianni C, et al."Real-world" data on the efficacy and safety of lenalidomide and dexameth- asone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: A study of the Greek Myeloma Study Group[J]. Ann Hematol, 2014, 93(1):129-139. [9] González Rodríguez AP.Management of the adverse effects of lenalidomide in multiple myeloma[J]. Adv Ther, 2011, 28(Suppl 1):1-10. [10] Dinner S, Witteles W, Afghahi A, et al.Lenalidomide, melpha-lan and dexamethasone in a population of patients with immun-oglobulin light chain amyloidosis with high rates of advancedcardiac involvement[J]. Haematologica, 2013, 98(10): 1593-1599. [11] 崔向丽,万子睿,侯珂露,等.增加肿瘤患者血栓风险的药物概述[J].中国药物警戒, 2017, 14(7): 430-434. [12] 张灵,王天元,师少军,等.来那度胺致药物性心肌炎1例[J].中国医院药学杂志, 2019, 39(7): 768-770. [13] 刘亚林,何清,王菁华,等.静注大剂量奥美拉唑导致心律失常[J].药物不良反应杂志, 2005, 7(5): 368-369. [14] 何启燕. 继发性低钾血症致室性心律失常的心电图特点及治疗策略分析[J].重庆医学, 2018, 47(20): 2742-2746. [15] 刘亦男摘译.无症状低血糖亦可诱发心律失常[J].中国糖尿病杂志, 2016, 24(3): 200-201. |